Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Project Grant

University of Toronto

$100,000.00

Comparative Benefits and Harms of Long-Term Osteoporosis Pharmacotherapy: Evidence to Inform Clinical Practice

FY 2019-20

Summary
Osteoporosis is a brittle bone condition that results in debilitating fractures. Over 2 million Canadians are affected by osteoporosis, and 1 in 3 women and 1 in 5 men will experience an osteoporotic fracture. Vertebral fractures reduce quality of life and are often accompanied by difficulty breathing and stomach issues related to a forward curvature of the upper spine. Hip fractures are deadly, 5% of patients do not survive their hospitalization and up to 33% die within the year after hip fracture. In addition, up to 24% enter a nursing home for the first time following hip fracture. Fortunately, treatment exists to prevent osteoporotic fractures. The bisphosphonate (BP) class of medications is first-line therapy and has been available for over 2 decades in Canada. Recent evidence has identified rare and serious possible harms of long-term BP use. BPs persist in bone, making them very effective and experimental evidence identifies that most men and women can safely stop BPs after a minimum of 3 to 5 years of therapy. However, little information is available to guide what to do following 3 to 5 years of initial treatment. Uncertainty about long-term osteoporosis treatment is the main knowledge gap identified in Osteoporosis Canada's Clinical Practice Guidelines that are currently being updated. We are working directly with Osteoporosis Canada to answer the main questions that doctors have about osteoporosis treatment: how long is enough, is long-term treatment with one BP safer or more harmful than another, how long can a patient remain off treatment before their fracture risk starts to rise again, and might a switch to denosumab (a newer medication available since 2012) be the best choice for extended treatment of osteoporosis among patients a high risk? Results will inform long-term treatment decisions for older men and women and thus significantly advance osteoporosis management world-wide by providing answers to the key questions that currently exist.
Program
Project Grant
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database

As published

Id
408960
Name
Cadarette Suzanne M
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Health Services and Policy Research
Theme2
Health systems / services
Prcname2
Health Services Evaluation & Interventions Research 2
Projecttitle
Comparative Benefits and Harms of Long-Term Osteoporosis Pharmacotherapy: Evidence to Inform Clinical Practice
Programtype2
Operating Grants
Orgnameinp2
University of Toronto
Cihramount2
$100,000
Cihrequipment2
$0
Programname2
Project Grant
Keyworddelim
Comparative Effectiveness Research; Drug Safety; Epidemiologic Methods; Osteoporosis; Pharmacoepidemiology; Real-World Evidence
Abstract
Osteoporosis is a brittle bone condition that results in debilitating fractures. Over 2 million Canadians are affected by osteoporosis, and 1 in 3 women and 1 in 5 men will experience an osteoporotic fracture. Vertebral fractures reduce quality of life and are often accompanied by difficulty breathing and stomach issues related to a forward curvature of the upper spine. Hip fractures are deadly, 5% of patients do not survive their hospitalization and up to 33% die within the year after hip fracture. In addition, up to 24% enter a nursing home for the first time following hip fracture. Fortunately, treatment exists to prevent osteoporotic fractures. The bisphosphonate (BP) class of medications is first-line therapy and has been available for over 2 decades in Canada. Recent evidence has identified rare and serious possible harms of long-term BP use. BPs persist in bone, making them very effective and experimental evidence identifies that most men and women can safely stop BPs after a minimum of 3 to 5 years of therapy. However, little information is available to guide what to do following 3 to 5 years of initial treatment. Uncertainty about long-term osteoporosis treatment is the main knowledge gap identified in Osteoporosis Canada's Clinical Practice Guidelines that are currently being updated. We are working directly with Osteoporosis Canada to answer the main questions that doctors have about osteoporosis treatment: how long is enough, is long-term treatment with one BP safer or more harmful than another, how long can a patient remain off treatment before their fracture risk starts to rise again, and might a switch to denosumab (a newer medication available since 2012) be the best choice for extended treatment of osteoporosis among patients a high risk? Results will inform long-term treatment decisions for older men and women and thus significantly advance osteoporosis management world-wide by providing answers to the key questions that currently exist.
Competitiondate
201909
Approvedterm2
2 yrs 0 mth
Pinamesdelim
Cadarette, Suzanne M; Hayes, Kaleen N
Approvedterm
2 ans 0 mois
Cihrcontribution2
~ $100,000~ $0~